Johnson & Johnson (NYSE:JNJ) Upgraded to Outperform by Sanford C. Bernstein

Sanford C. Bernstein upgraded shares of Johnson & Johnson (NYSE:JNJ) from a market perform rating to an outperform rating in a report published on Friday morning, BenzingaRatingsTable reports. They currently have $155.00 target price on the stock.

JNJ has been the topic of several other research reports. Credit Suisse Group set a $156.00 price target on Johnson & Johnson and gave the stock a buy rating in a research report on Tuesday, August 27th. Zacks Investment Research lowered Johnson & Johnson from a buy rating to a hold rating and set a $139.00 price target on the stock. in a research report on Thursday, July 18th. Bank of America reaffirmed a hold rating and set a $150.00 price target on shares of Johnson & Johnson in a research report on Tuesday, July 16th. Morgan Stanley reaffirmed an equal weight rating and set a $145.00 price target on shares of Johnson & Johnson in a research report on Tuesday, August 27th. Finally, Barclays assumed coverage on Johnson & Johnson in a research report on Friday, June 21st. They set a hold rating and a $140.00 price target on the stock. Five analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Johnson & Johnson currently has an average rating of Buy and a consensus price target of $151.00.

Shares of NYSE:JNJ traded up $2.27 during trading on Friday, hitting $131.33. 6,386,443 shares of the company were exchanged, compared to its average volume of 6,784,859. The stock has a market cap of $341.03 billion, a price-to-earnings ratio of 16.06, a P/E/G ratio of 2.18 and a beta of 0.69. Johnson & Johnson has a fifty-two week low of $121.00 and a fifty-two week high of $148.99. The firm has a fifty day moving average price of $129.92 and a two-hundred day moving average price of $134.97. The company has a current ratio of 1.33, a quick ratio of 1.04 and a debt-to-equity ratio of 0.46.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, July 16th. The company reported $2.58 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.42 by $0.16. The firm had revenue of $20.56 billion for the quarter, compared to analyst estimates of $20.39 billion. Johnson & Johnson had a return on equity of 38.63% and a net margin of 20.08%. The business’s quarterly revenue was down 1.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.10 EPS. As a group, research analysts predict that Johnson & Johnson will post 8.59 EPS for the current year.

Hedge funds have recently bought and sold shares of the stock. Virtus ETF Advisers LLC acquired a new position in shares of Johnson & Johnson during the 2nd quarter worth approximately $25,000. Krane Funds Advisors LLC bought a new stake in Johnson & Johnson in the 2nd quarter valued at $26,000. Crewe Advisors LLC boosted its stake in Johnson & Johnson by 725.9% in the 2nd quarter. Crewe Advisors LLC now owns 223 shares of the company’s stock valued at $31,000 after purchasing an additional 196 shares during the period. Permanens Capital L.P. boosted its stake in Johnson & Johnson by 50.0% in the 2nd quarter. Permanens Capital L.P. now owns 300 shares of the company’s stock valued at $42,000 after purchasing an additional 100 shares during the period. Finally, Thor Advisors LLC bought a new stake in Johnson & Johnson in the 1st quarter valued at $69,000. 72.01% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Read More: Trading Options- What is a Strangle?

Analyst Recommendations for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.